RU2002129353A - Терапевтические сочетания гипотензивного и антиангиогенного лекарственных средств - Google Patents
Терапевтические сочетания гипотензивного и антиангиогенного лекарственных средствInfo
- Publication number
- RU2002129353A RU2002129353A RU2002129353/14A RU2002129353A RU2002129353A RU 2002129353 A RU2002129353 A RU 2002129353A RU 2002129353/14 A RU2002129353/14 A RU 2002129353/14A RU 2002129353 A RU2002129353 A RU 2002129353A RU 2002129353 A RU2002129353 A RU 2002129353A
- Authority
- RU
- Russia
- Prior art keywords
- methoxy
- quinazoline
- yloxy
- agent
- use according
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract 4
- 230000001772 anti-angiogenic effect Effects 0.000 title claims 2
- 208000001953 Hypotension Diseases 0.000 title 1
- 208000021822 hypotensive Diseases 0.000 title 1
- 230000001077 hypotensive effect Effects 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims abstract 14
- 239000002220 antihypertensive agent Substances 0.000 claims abstract 10
- 229940030600 antihypertensive agent Drugs 0.000 claims abstract 8
- 230000033115 angiogenesis Effects 0.000 claims abstract 4
- 201000010099 disease Diseases 0.000 claims abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 4
- 241001465754 Metazoa Species 0.000 claims abstract 3
- 241000124008 Mammalia Species 0.000 claims abstract 2
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims 7
- 229940002612 prodrug Drugs 0.000 claims 5
- 239000000651 prodrug Substances 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- -1 4-fluorindol-5-yloxy Chemical group 0.000 claims 2
- 239000005541 ACE inhibitor Substances 0.000 claims 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- GCABIYVOJWRUBO-MRXNPFEDSA-N (2r)-1-[4-[(4-fluoro-2-methyl-1h-indol-5-yl)oxy]-6-methoxyquinazolin-7-yl]oxy-3-pyrrolidin-1-ylpropan-2-ol Chemical compound C([C@@H](O)COC1=CC2=NC=NC(OC=3C(=C4C=C(C)NC4=CC=3)F)=C2C=C1OC)N1CCCC1 GCABIYVOJWRUBO-MRXNPFEDSA-N 0.000 claims 1
- YAIZIOMJNQKWHW-UHFFFAOYSA-N 4-[(4-fluoro-1h-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=CNC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 YAIZIOMJNQKWHW-UHFFFAOYSA-N 0.000 claims 1
- QLKYLLNKQLYUCK-UHFFFAOYSA-N 4-[(4-fluoro-1h-indol-5-yl)oxy]-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=CNC4=CC=3)F)N=CN=C2C=C1OCC1CCN(C)CC1 QLKYLLNKQLYUCK-UHFFFAOYSA-N 0.000 claims 1
- QIAQSHWCWZYWDB-UHFFFAOYSA-N 4-[(4-fluoro-1h-indol-5-yl)oxy]-6-methoxy-7-[2-(1-methylpiperidin-4-yl)ethoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=CNC4=CC=3)F)N=CN=C2C=C1OCCC1CCN(C)CC1 QIAQSHWCWZYWDB-UHFFFAOYSA-N 0.000 claims 1
- OWHNSMAGPUBAHX-UHFFFAOYSA-N 4-[(4-fluoro-1h-indol-5-yl)oxy]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=CNC4=CC=3)F)N=CN=C2C=C1OCCCN1CCN(C)CC1 OWHNSMAGPUBAHX-UHFFFAOYSA-N 0.000 claims 1
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 claims 1
- NZMWZMBJACHTSF-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1h-indol-5-yl)oxy]-6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCCC1 NZMWZMBJACHTSF-UHFFFAOYSA-N 0.000 claims 1
- XWOGDYNDOQKNBW-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1h-indol-5-yl)oxy]-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCC1CCN(C)CC1 XWOGDYNDOQKNBW-UHFFFAOYSA-N 0.000 claims 1
- WKHMXMYWJGLMDQ-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1h-indol-5-yl)oxy]-6-methoxy-7-[2-(1-methylpiperidin-4-yl)ethoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCC1CCN(C)CC1 WKHMXMYWJGLMDQ-UHFFFAOYSA-N 0.000 claims 1
- UBQBLLUOQUWFBD-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1h-indol-5-yl)oxy]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCN(C)CC1 UBQBLLUOQUWFBD-UHFFFAOYSA-N 0.000 claims 1
- CUXRYZZQLQTALS-UHFFFAOYSA-N 4-[(6-fluoro-1h-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline Chemical compound COC1=CC2=C(OC=3C(=CC=4NC=CC=4C=3)F)N=CN=C2C=C1OCCCN1CCCC1 CUXRYZZQLQTALS-UHFFFAOYSA-N 0.000 claims 1
- VWIOUOMKJGDTHR-UHFFFAOYSA-N 6-methoxy-4-[(2-methyl-1h-indol-5-yl)oxy]-7-(3-pyrrolidin-1-ylpropoxy)quinazoline Chemical compound COC1=CC2=C(OC=3C=C4C=C(C)NC4=CC=3)N=CN=C2C=C1OCCCN1CCCC1 VWIOUOMKJGDTHR-UHFFFAOYSA-N 0.000 claims 1
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- 108010007859 Lisinopril Proteins 0.000 claims 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 229940097320 beta blocking agent Drugs 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 229960000830 captopril Drugs 0.000 claims 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229960002394 lisinopril Drugs 0.000 claims 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 claims 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical group C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical group COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims 1
- 230000008728 vascular permeability Effects 0.000 claims 1
- 239000004066 vascular targeting agent Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0008269.3 | 2000-04-05 | ||
| GBGB0008269.3A GB0008269D0 (en) | 2000-04-05 | 2000-04-05 | Combination chemotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2002129353A true RU2002129353A (ru) | 2004-03-20 |
Family
ID=9889176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2002129353/14A RU2002129353A (ru) | 2000-04-05 | 2001-04-02 | Терапевтические сочетания гипотензивного и антиангиогенного лекарственных средств |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US7829573B2 (enExample) |
| EP (3) | EP1658849A3 (enExample) |
| JP (1) | JP2003528917A (enExample) |
| KR (2) | KR20080034523A (enExample) |
| CN (1) | CN1431902A (enExample) |
| AT (1) | ATE355065T1 (enExample) |
| AU (2) | AU2001244386B2 (enExample) |
| BR (1) | BR0109729A (enExample) |
| CA (1) | CA2401854A1 (enExample) |
| CY (1) | CY1107615T1 (enExample) |
| CZ (1) | CZ299410B6 (enExample) |
| DE (1) | DE60126923T2 (enExample) |
| DK (1) | DK1272186T3 (enExample) |
| EE (1) | EE200200578A (enExample) |
| ES (1) | ES2280349T3 (enExample) |
| GB (1) | GB0008269D0 (enExample) |
| HU (1) | HUP0300426A2 (enExample) |
| IL (1) | IL151503A0 (enExample) |
| IS (2) | IS2455B (enExample) |
| MX (1) | MXPA02009743A (enExample) |
| NO (2) | NO323467B1 (enExample) |
| NZ (2) | NZ534455A (enExample) |
| PL (1) | PL357605A1 (enExample) |
| PT (1) | PT1272186E (enExample) |
| RU (1) | RU2002129353A (enExample) |
| SI (1) | SI1272186T1 (enExample) |
| SK (1) | SK14302002A3 (enExample) |
| WO (1) | WO2001074360A1 (enExample) |
| ZA (1) | ZA200206959B (enExample) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7381413B1 (en) * | 1998-04-17 | 2008-06-03 | University Of Vermont And State Agricultural College | Methods and products related to metabolic interactions in disease |
| EP1676845B1 (en) | 1999-11-05 | 2008-06-11 | AstraZeneca AB | New quinazoline derivatives |
| US7498335B2 (en) | 2000-03-06 | 2009-03-03 | Astrazeneca Ab | Method of producing an antiangiogenic or vascular permeability reducing effect |
| EP1274692B1 (en) | 2000-04-07 | 2006-08-02 | AstraZeneca AB | Quinazoline compounds |
| GB0126879D0 (en) * | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
| NZ534171A (en) * | 2002-02-01 | 2007-06-29 | Astrazeneca Ab | Quinazoline compounds for the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
| DE60311788T2 (de) * | 2002-04-16 | 2007-11-22 | Astrazeneca Ab | Kombinationstherapie zur behandlung von krebs |
| US7358236B1 (en) * | 2002-06-21 | 2008-04-15 | Oxigene, Inc. | Control of acute hypertension and cardiotoxicity in patients treated with vascular targeting agents |
| EP1521747B1 (en) * | 2002-07-15 | 2018-09-05 | Symphony Evolution, Inc. | Receptor-type kinase modulators and methods of use |
| US7335362B2 (en) * | 2002-07-19 | 2008-02-26 | Beth Israel Deaconess Medical Center | Methods of treating pre-eclampsia or eclampsia |
| KR101215701B1 (ko) * | 2002-07-19 | 2012-12-26 | 베스 이스라엘 데코니스 메디칼 센터 | 자간전증 또는 자간의 진단 및 치료 방법 |
| US7435419B2 (en) * | 2002-07-19 | 2008-10-14 | Beth Israel Deaconess Medical Center | Methods of diagnosing and treating pre-eclampsia or eclampsia |
| GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
| GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
| NZ539408A (en) | 2002-11-04 | 2007-09-28 | Astrazeneca Ab | Quinazoline derivatives as SRC tyrosine kinase inhibitors for treating solid tumours |
| CA2514227C (en) * | 2003-02-13 | 2011-08-09 | Astrazeneca Ab | Combination therapy of zd6474 with 5-fu or/and cpt-11 |
| GB0307333D0 (en) * | 2003-03-29 | 2003-05-07 | Astrazeneca Ab | Therapeutic agent |
| GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
| WO2004112801A2 (en) * | 2003-06-18 | 2004-12-29 | Angiogene Pharmaceuticals Limited | Compositions comprising zd6126 together with 5-fu, cpt-11 or 5-fu and cpt-11 having vascular damaging activity for treating e.g. colorectal cancer |
| GB0316123D0 (en) * | 2003-07-10 | 2003-08-13 | Astrazeneca Ab | Combination therapy |
| BRPI0412426A (pt) * | 2003-07-10 | 2006-09-05 | Astrazeneca Ab | uso da zd6474 ou de um sal farmaceuticamente aceitável da mesma e de um agente antitumoral de platina, composição farmacêutica, kit, e método para a produção de um efeito antiangiogênico e/ou redutor de permeabilidade vascular em um animal de sangue quente |
| GB0316127D0 (en) * | 2003-07-10 | 2003-08-13 | Astrazeneca Ab | Combination therapy |
| GB0318422D0 (en) | 2003-08-06 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
| MXPA06002296A (es) | 2003-08-29 | 2006-05-22 | Pfizer | Tienopiridina-fenilacetamidas y sus derivados utiles como nuevos agentes antiangiogenicos. |
| MXPA06007242A (es) | 2003-12-23 | 2006-08-18 | Pfizer | Nuevos derivados de quinolina. |
| GB0330002D0 (en) | 2003-12-24 | 2004-01-28 | Astrazeneca Ab | Quinazoline derivatives |
| GB0406445D0 (en) * | 2004-03-23 | 2004-04-28 | Astrazeneca Ab | Combination therapy |
| KR20060130764A (ko) * | 2004-03-23 | 2006-12-19 | 아스트라제네카 아베 | 병용 요법 |
| US20070142433A1 (en) * | 2004-04-06 | 2007-06-21 | Helmut Augustin | Angiogenesis-affecting compounds and methods of use thereof |
| US20070142308A1 (en) * | 2005-04-06 | 2007-06-21 | Helmut Augustin | Angiogenesis-affecting compounds and methods for use thereof |
| EP1737452A1 (en) * | 2004-04-06 | 2007-01-03 | Angiogenetics Sweden AB | Angiogenesis-affecting compounds and methods of use thereof |
| JP2007536251A (ja) * | 2004-05-04 | 2007-12-13 | チルドレンズ メディカル センター コーポレーション | 子癇前症の処置のための方法および組成物 |
| EP1750862B1 (en) | 2004-06-04 | 2011-01-05 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition containing irbesartan |
| MX2007003522A (es) * | 2004-09-24 | 2007-06-11 | Beth Israel Hospital | Complicaciones del embarazo. |
| US7740849B2 (en) * | 2004-09-24 | 2010-06-22 | Beth Israel Deaconess Medical Center | Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders |
| BRPI0516052A (pt) * | 2004-09-27 | 2008-08-19 | Astrazeneca Ab | uso de zd6474 ou de um sal farmaceuticamente aceitável do mesmo e de imatinib, composição farmacêutica, kit, e, método para a produção de um efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente |
| GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
| WO2006063048A2 (en) * | 2004-12-06 | 2006-06-15 | Avigen, Inc. | Ibudilast for treating neuropathic pain and associated syndromes |
| DE602005023216D1 (de) * | 2004-12-15 | 2010-10-07 | Beth Israel Hospital | Nukleinsäuren und polypeptide zur diagnose und behandlung von schwangerschaftskomplikationen |
| EP1853298A2 (en) * | 2005-02-11 | 2007-11-14 | Regeneron Pharmaceuticals, Inc. | Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent |
| CA2600868A1 (en) * | 2005-03-09 | 2006-09-21 | Merck & Co., Inc. | Quinazolinone t-type calcium channel antagonists |
| WO2007003933A2 (en) * | 2005-07-06 | 2007-01-11 | Astrazeneca Ab | Combination therapy of cancer with azd2171 and gemcitabine |
| KR20080027923A (ko) | 2005-08-08 | 2008-03-28 | 화이자 인코포레이티드 | Ｖｅｇｆ-ｒ 억제제의 염 및 다형체 |
| AU2006279658A1 (en) | 2005-08-12 | 2007-02-22 | Regeneron Pharmaceuticals, Inc. | Treatment of diseases by subcutaneous administration of a VEGF antagonist |
| EP1971338B8 (en) * | 2005-12-22 | 2011-09-21 | AstraZeneca AB | Combination of zd6474 and pemetrexed |
| PT1965801E (pt) * | 2005-12-22 | 2011-05-25 | Astrazeneca Ab | Combina??o de azd2171 e pemetrexed |
| US20090286271A1 (en) * | 2006-05-31 | 2009-11-19 | Karumanchi Ananth S | Methods of Diagnosing and Treating Complications of Pregnancy |
| US20100092466A1 (en) * | 2006-09-29 | 2010-04-15 | Anderson Joseph Ryan | Combination of zd6474 and bevacizumab for cancer therapy |
| WO2008080110A1 (en) * | 2006-12-21 | 2008-07-03 | Alcon, Inc. | Methods for treating macular edema and pathologic ocular angiogenesis using a neuroprotective agent and a receptor tyrosine kinase inhibitor |
| US20080181876A1 (en) * | 2007-01-30 | 2008-07-31 | Johnson Kirk W | Methods for treating acute and subchronic pain |
| US20080190689A1 (en) * | 2007-02-12 | 2008-08-14 | Ballard Ebbin C | Inserts for engine exhaust systems |
| US20100087398A1 (en) * | 2007-05-02 | 2010-04-08 | Tau Therapeutics Llc | Dihydropyridine derivative for treating cancer or a pre-cancerous condition and other conditions |
| WO2008137012A1 (en) * | 2007-05-03 | 2008-11-13 | Avigen, Inc. | Use of a glial attenuator to prevent amplified pain responses caused by glial priming |
| CA2692783A1 (en) * | 2007-07-10 | 2009-01-15 | Merck Sharp & Dohme Corp. | Quinazolinone t-type calcium channel antagonists |
| AU2009271579A1 (en) | 2008-07-14 | 2010-01-21 | The Regents Of The University Of Colorado | Methods and products for treating proliferative diseases |
| CA2787673A1 (en) | 2010-03-01 | 2011-09-09 | Tau Therapeutics Llc | Cancer diagnosis and imaging |
| JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
| CN103110614B (zh) * | 2013-01-18 | 2015-02-18 | 杭州雷索药业有限公司 | 舒洛地尔在制备抗血管生成类药物中的应用 |
| CN105189462B (zh) | 2013-02-20 | 2017-11-10 | 卡拉制药公司 | 治疗性化合物和其用途 |
| EP3129015B1 (en) | 2014-04-08 | 2021-07-14 | The Methodist Hospital | Inos-inhibitory compositions and their use as breast cancer therapeutics |
| HRP20191145T1 (hr) | 2014-07-18 | 2019-10-04 | Sanofi | Postupak predviđanja ishoda liječenja s afliberceptom kod pacijenta za kojeg se sumnja da ima rak |
| US10265111B2 (en) | 2016-04-26 | 2019-04-23 | Medtronic Holding Company Sárl | Inflatable bone tamp with flow control and methods of use |
| US10799138B2 (en) | 2018-04-05 | 2020-10-13 | University Of Maryland, Baltimore | Method of administering sotalol IV/switch |
| WO2020028007A1 (en) * | 2018-07-31 | 2020-02-06 | Colorado State University Research Foundation | Compositions, methods and uses for modulating the tumor microenvironment to enhance antitumor immunity |
| US11610660B1 (en) | 2021-08-20 | 2023-03-21 | AltaThera Pharmaceuticals LLC | Antiarrhythmic drug dosing methods, medical devices, and systems |
| US11696902B2 (en) | 2018-08-14 | 2023-07-11 | AltaThera Pharmaceuticals, LLC | Method of initiating and escalating sotalol hydrochloride dosing |
| US10512620B1 (en) | 2018-08-14 | 2019-12-24 | AltaThera Pharmaceuticals, LLC | Method of initiating and escalating sotalol hydrochloride dosing |
| US11344518B2 (en) | 2018-08-14 | 2022-05-31 | AltaThera Pharmaceuticals LLC | Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame |
| US12396970B2 (en) | 2021-08-20 | 2025-08-26 | AltaThera Pharmaceuticals LLC | Anti-arrhythmic compositions and methods |
| US11484355B2 (en) | 2020-03-02 | 2022-11-01 | Medtronic Holding Company Sàrl | Inflatable bone tamp and method for use of inflatable bone tamp |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4010797A1 (de) | 1990-04-04 | 1991-10-10 | Hoechst Ag | Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung |
| US5646136A (en) * | 1994-01-04 | 1997-07-08 | Duke University | Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids |
| GB9624482D0 (en) * | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| BR9707495A (pt) * | 1996-02-13 | 1999-07-27 | Zeneca Ltd | Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente |
| JP4464466B2 (ja) * | 1996-03-05 | 2010-05-19 | アストラゼネカ・ユーケイ・リミテッド | ４―アニリノキナゾリン誘導体 |
| WO1997034876A1 (en) * | 1996-03-15 | 1997-09-25 | Zeneca Limited | Cinnoline derivatives and use as medicine |
| GB9707800D0 (en) * | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
| JP2001500890A (ja) * | 1996-09-25 | 2001-01-23 | ゼネカ リミテッド | Ｖｅｇｆのような成長因子の作用を阻害するキノリン誘導体 |
| GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| CA2275708A1 (en) | 1996-12-23 | 1998-07-02 | Cambridge University Technical Services Limited | Diagnosis and treatment of pathological pregnancies |
| US6294532B1 (en) * | 1997-08-22 | 2001-09-25 | Zeneca Limited | Oxindolylquinazoline derivatives as angiogenesis inhibitors |
| ES2389387T3 (es) * | 1998-03-17 | 2012-10-25 | Genentech, Inc. | Polipéptidos homólogos de VEGF y de BMP1 |
| US6191144B1 (en) * | 1998-08-17 | 2001-02-20 | Warner-Lambert Company | Method of using angiotensin converting enzyme inhibitor to stimulate angiogenesis |
| ES2211165T3 (es) | 1998-09-09 | 2004-07-01 | Scios Inc. | Uso de un factor angiogenico para el tratamiento de angiopatias microvasculares. |
| WO2000041712A1 (en) * | 1999-01-15 | 2000-07-20 | Cardiovascular Research Foundation | Inhibiting development of microvessels within vascular walls |
| PL199802B1 (pl) | 1999-02-10 | 2008-10-31 | Astrazeneca Ab | Pochodne chinazoliny, sposoby ich wytwarzania, ich kompozycje farmaceutyczne i ich zastosowania |
| EP1676845B1 (en) * | 1999-11-05 | 2008-06-11 | AstraZeneca AB | New quinazoline derivatives |
| AU8054601A (en) * | 2000-07-13 | 2002-02-05 | Alteon Inc | Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disordersassociated with protein aging |
| GB0126879D0 (en) | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
| EP1534287A1 (en) | 2002-08-09 | 2005-06-01 | Astrazeneca AB | Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer |
| GB0218526D0 (en) | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
| GB0223380D0 (en) | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
| CA2514227C (en) | 2003-02-13 | 2011-08-09 | Astrazeneca Ab | Combination therapy of zd6474 with 5-fu or/and cpt-11 |
| GB0310401D0 (en) | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
| GB0316123D0 (en) | 2003-07-10 | 2003-08-13 | Astrazeneca Ab | Combination therapy |
| GB0316127D0 (en) | 2003-07-10 | 2003-08-13 | Astrazeneca Ab | Combination therapy |
| BRPI0412426A (pt) | 2003-07-10 | 2006-09-05 | Astrazeneca Ab | uso da zd6474 ou de um sal farmaceuticamente aceitável da mesma e de um agente antitumoral de platina, composição farmacêutica, kit, e método para a produção de um efeito antiangiogênico e/ou redutor de permeabilidade vascular em um animal de sangue quente |
| GB0406446D0 (en) | 2004-03-23 | 2004-04-28 | Astrazeneca Ab | Combination therapy |
| GB0406445D0 (en) | 2004-03-23 | 2004-04-28 | Astrazeneca Ab | Combination therapy |
| KR20060130764A (ko) | 2004-03-23 | 2006-12-19 | 아스트라제네카 아베 | 병용 요법 |
| JP2008514576A (ja) | 2004-09-27 | 2008-05-08 | アストラゼネカ アクチボラグ | Ａｚｄ２１７１およびイマチニブを含む癌組合せ療法 |
| BRPI0516052A (pt) | 2004-09-27 | 2008-08-19 | Astrazeneca Ab | uso de zd6474 ou de um sal farmaceuticamente aceitável do mesmo e de imatinib, composição farmacêutica, kit, e, método para a produção de um efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente |
| GB0424339D0 (en) | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
| WO2007003933A2 (en) | 2005-07-06 | 2007-01-11 | Astrazeneca Ab | Combination therapy of cancer with azd2171 and gemcitabine |
| CN101370519B (zh) | 2005-12-15 | 2013-07-24 | 阿斯利康(瑞典)有限公司 | 治疗癌症的促血管生成素-2拮抗剂和VEGF-A、KDR和/或Flt1拮抗剂的组合 |
| EP1971338B8 (en) | 2005-12-22 | 2011-09-21 | AstraZeneca AB | Combination of zd6474 and pemetrexed |
| PT1965801E (pt) | 2005-12-22 | 2011-05-25 | Astrazeneca Ab | Combina??o de azd2171 e pemetrexed |
| US20100092466A1 (en) | 2006-09-29 | 2010-04-15 | Anderson Joseph Ryan | Combination of zd6474 and bevacizumab for cancer therapy |
| WO2008125820A1 (en) | 2007-04-13 | 2008-10-23 | Astrazeneca Ab | Combination therapy comprising azd2171 and azd6244 or mek-inhibitor ii |
-
2000
- 2000-04-05 GB GBGB0008269.3A patent/GB0008269D0/en not_active Ceased
-
2001
- 2001-04-02 EP EP06003576A patent/EP1658849A3/en not_active Withdrawn
- 2001-04-02 IL IL15150301A patent/IL151503A0/xx unknown
- 2001-04-02 WO PCT/GB2001/001522 patent/WO2001074360A1/en not_active Ceased
- 2001-04-02 CN CN01807430A patent/CN1431902A/zh active Pending
- 2001-04-02 NZ NZ534455A patent/NZ534455A/en unknown
- 2001-04-02 KR KR1020087007835A patent/KR20080034523A/ko not_active Ceased
- 2001-04-02 AT AT01917305T patent/ATE355065T1/de active
- 2001-04-02 ES ES01917305T patent/ES2280349T3/es not_active Expired - Lifetime
- 2001-04-02 EP EP07003863A patent/EP1790340A3/en not_active Withdrawn
- 2001-04-02 SI SI200130715T patent/SI1272186T1/sl unknown
- 2001-04-02 PT PT01917305T patent/PT1272186E/pt unknown
- 2001-04-02 RU RU2002129353/14A patent/RU2002129353A/ru unknown
- 2001-04-02 CZ CZ20023304A patent/CZ299410B6/cs not_active IP Right Cessation
- 2001-04-02 EE EEP200200578A patent/EE200200578A/xx unknown
- 2001-04-02 PL PL01357605A patent/PL357605A1/xx not_active Application Discontinuation
- 2001-04-02 CA CA002401854A patent/CA2401854A1/en not_active Abandoned
- 2001-04-02 DE DE60126923T patent/DE60126923T2/de not_active Expired - Lifetime
- 2001-04-02 JP JP2001572104A patent/JP2003528917A/ja active Pending
- 2001-04-02 BR BR0109729-6A patent/BR0109729A/pt not_active Application Discontinuation
- 2001-04-02 SK SK1430-2002A patent/SK14302002A3/sk unknown
- 2001-04-02 KR KR1020027013170A patent/KR100849149B1/ko not_active Expired - Fee Related
- 2001-04-02 HU HU0300426A patent/HUP0300426A2/hu unknown
- 2001-04-02 MX MXPA02009743A patent/MXPA02009743A/es active IP Right Grant
- 2001-04-02 AU AU2001244386A patent/AU2001244386B2/en not_active Ceased
- 2001-04-02 DK DK01917305T patent/DK1272186T3/da active
- 2001-04-02 EP EP01917305A patent/EP1272186B1/en not_active Expired - Lifetime
- 2001-04-02 AU AU4438601A patent/AU4438601A/xx active Pending
- 2001-04-02 US US10/240,413 patent/US7829573B2/en not_active Expired - Fee Related
- 2001-04-02 NZ NZ520938A patent/NZ520938A/en unknown
-
2002
- 2002-08-29 ZA ZA200206959A patent/ZA200206959B/en unknown
- 2002-09-20 IS IS6557A patent/IS2455B/is unknown
- 2002-10-04 NO NO20024814A patent/NO323467B1/no not_active IP Right Cessation
-
2006
- 2006-05-08 NO NO20062050A patent/NO326277B1/no not_active IP Right Cessation
-
2007
- 2007-04-17 CY CY20071100523T patent/CY1107615T1/el unknown
-
2008
- 2008-04-16 IS IS8726A patent/IS8726A/is unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2002129353A (ru) | Терапевтические сочетания гипотензивного и антиангиогенного лекарственных средств | |
| JP2003528917A5 (enExample) | ||
| RU2407532C2 (ru) | Комбинации, предназначенные для лечения заболеваний, включающих пролиферацию клеток | |
| RU2002114809A (ru) | Производные хиназолина в качестве ингибиторов васкулярного эндотелиального фактора роста (vegf) | |
| RU2357734C2 (ru) | КОМБИНАЦИЯ АНТАГОНИСТА РЕЦЕПТОРА mGluR2 И ИНГИБИТОРА ФЕРМЕНТА AChE ДЛЯ ЛЕЧЕНИЯ ОСТРЫХ И/ИЛИ ХРОНИЧЕСКИХ НЕВРОЛОГИЧЕСКИХ ЗАБОЛЕВАНИЙ | |
| US20090209496A1 (en) | Methods and compositions for enhancing the efficacy of rtk inhibitors | |
| JP4694127B2 (ja) | Ｚｄ６４７４とタキサンとを含む組み合わせ療法 | |
| RU2018120330A (ru) | Химерные соединения, осуществляющие нацеливание для протеолиза, и способы их получения и применения | |
| BR0110877A (pt) | Métodos de tratamento de câncer primário, de aumento da dosagem de um inibidor de topoisomerase, de redução ou prevenção de um efeito adverso associado com quimioterapia e com terapia de radiação, de aumento da eficácia terapêutica de um inibidor de topoisomerase, e de proteção de um paciente canceroso dos efeitos adversos associados com a administração de uma droga anti-câncer, composição farmacêutica, forma de dosagem, e, kit para uso no tratamento de câncer | |
| JP2024532374A (ja) | Ｔｅａｄ阻害剤を含む医薬品組み合わせ物及び癌の治療のためのその使用 | |
| KR20020018201A (ko) | 결장 폴립 및 결장직장암의 치료 또는 억제용엔에스에이아이디 및 이지에프알 키나제 억제제 함유 조성물 | |
| ATE551060T1 (de) | Zusammensetzungen und verfahren zur behandlung von neovaskulären erkrankungen | |
| EP1326611A4 (en) | AZA AND POLYAZA NAPHTHALENYL CARBONIC ACID AMIDES AS HIV INTEGRASE INHIBITORS | |
| DE69709319D1 (de) | 4-anilinochinazolin derivate | |
| RU2007134570A (ru) | Антиангиогенные средства с алдеслейкином | |
| RU2003133216A (ru) | Фармацевтические комбинации | |
| EP1336407A4 (en) | MEDICAL COMPOSITIONS | |
| RU2350618C2 (ru) | ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ | |
| JP2011512399A (ja) | 卵巣癌を治療するための、パクリタキセルを含む配合剤 | |
| RU2011122542A (ru) | Способ ингибирования рецепторных тирозинкиназ с помощью внеклеточного антагониста и внутриклеточного антагониста | |
| JPWO2021177721A5 (enExample) | ||
| AR053357A1 (es) | Uso de un inhibidor de quinasa del receptor del factor de crecimiento epidermico (efgr) en pacientes resistentes a gefitinib | |
| WO2004032925A1 (en) | Use of imatinib (glivec, sti-571) to inhibit breast cancer resistance protein (bcrp)-mediated resistance to therapeutic agents | |
| US20150209362A1 (en) | Pharmaceutical combinations comprising a pyrido [4,3-d] pyrimidine derived hsp90-inhibitor and a her2 inhibitor | |
| RU2007101161A (ru) | Производные 4-фенилпиримидин-2-карбонитрила |